Analysis of risk factors for all cause-mortality in Chinese emergency atrial fibrillation patients

National Medical Journal of China

Volumn 93, Issue 36, 2013, Pages 2871-2875

  Wang, Juan ^a   Yang, Yan Min ^a   Zhu, Jun ^a   Zhang, Han ^a   Shao, Xing Hui ^a   Huang, Bi ^a   Tian, Li ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atrial fibrillation; Emergency service; Hospital; Mortality; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; DIGOXIN; DIURETIC AGENT; HEPARIN;

ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; EMERGENCY WARD; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MEDICAL HISTORY; PREDICTIVE VALUE; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CHINA; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84886734596     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2013.36.007     Document Type: Article

References (20)

1. Wann L S, Curtis A B, January C T, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011, 123: 104-123.
2. 2004, 43: 491-494.
3. Jabre P, Roger V L, Murad M H, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation, 2011, 123: 1587-1593.
4. Andersson T, Magnuson A, Bryngelsson I L, et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J, 2013, 34: 1061-1067.
5. Eikelboom J W, Wallentin L, Connolly S J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation, 2011, 123: 2363-2372.
6. Connolly S J, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011, 364: 806-817.
7. Patel M R, Mahaffey K W, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365: 883-891.
8. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation, 1999, 99: 3028-3035.
9. Nieuwlaat R, Prins M H, Le Heuzey J Y, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J, 2008, 29: 1181-1189.
10. Atzema C L, Austin P C, Chong A S, et al. Factors associated with 90-day death after emergency department discharge for atrial fibrillation. Ann Emerg Med, 2013, 61: 539-548.
11. Keating R J, Gersh B J, Hodge D O, et al. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol, 2005, 96: 1420-1424.
12. Corley S D, Epstein A E, Dimarco J P, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 2004, 109: 1509-1513.
13. 2012, 92: 2671-2673.
14. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med, 2011, 155: 660-667, W204.
15. Crandall M A, Horne B D, Day J D, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol, 2009, 32: 981-986.
16. 2011, 91: 2665-2667.
17. Okin P M, Devereux R B, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation, 2003, 108: 684-690.
18. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet, 2007, 369: 1431-1439.
19. Cohn J N, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345: 1667-1675.
20. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol, 2005, 45: 712-719.